全文获取类型
收费全文 | 5826篇 |
免费 | 336篇 |
国内免费 | 24篇 |
专业分类
耳鼻咽喉 | 57篇 |
儿科学 | 84篇 |
妇产科学 | 71篇 |
基础医学 | 865篇 |
口腔科学 | 186篇 |
临床医学 | 352篇 |
内科学 | 1354篇 |
皮肤病学 | 54篇 |
神经病学 | 452篇 |
特种医学 | 298篇 |
外科学 | 632篇 |
综合类 | 23篇 |
预防医学 | 210篇 |
眼科学 | 259篇 |
药学 | 521篇 |
中国医学 | 11篇 |
肿瘤学 | 757篇 |
出版年
2023年 | 18篇 |
2022年 | 46篇 |
2021年 | 87篇 |
2020年 | 34篇 |
2019年 | 47篇 |
2018年 | 63篇 |
2017年 | 52篇 |
2016年 | 77篇 |
2015年 | 84篇 |
2014年 | 123篇 |
2013年 | 163篇 |
2012年 | 225篇 |
2011年 | 258篇 |
2010年 | 147篇 |
2009年 | 123篇 |
2008年 | 258篇 |
2007年 | 277篇 |
2006年 | 275篇 |
2005年 | 257篇 |
2004年 | 278篇 |
2003年 | 256篇 |
2002年 | 285篇 |
2001年 | 247篇 |
2000年 | 266篇 |
1999年 | 241篇 |
1998年 | 96篇 |
1997年 | 77篇 |
1996年 | 71篇 |
1995年 | 60篇 |
1994年 | 53篇 |
1993年 | 53篇 |
1992年 | 144篇 |
1991年 | 185篇 |
1990年 | 173篇 |
1989年 | 163篇 |
1988年 | 149篇 |
1987年 | 130篇 |
1986年 | 127篇 |
1985年 | 93篇 |
1984年 | 74篇 |
1983年 | 49篇 |
1982年 | 34篇 |
1981年 | 27篇 |
1980年 | 15篇 |
1979年 | 49篇 |
1978年 | 41篇 |
1977年 | 31篇 |
1976年 | 24篇 |
1975年 | 11篇 |
1966年 | 8篇 |
排序方式: 共有6186条查询结果,搜索用时 31 毫秒
91.
Laminin M is found in placental basement membranes, but not in basement membranes of neoplastic origin 总被引:2,自引:0,他引:2
Laminin is a high molecular weight glycoprotein found in all basement membranes studied to date. Two subunits of laminin, A and B, have been isolated and characterized from a variety of tumor matrices. Recently we have reported the finding, in human placenta, of a new laminin subunit which we termed M. In the present study we report on the presence of laminin M in placentae of other species such as bovine, rat and mouse. In addition, we have examined laminin extracted from mouse EHS-tumor, rat ED-PYS carcinoma and three human carcinoma cell lines. The laminin subunits were detected by the electroimmunoblot technique using antibodies against mouse, rat and human laminin. Laminin M could not be demonstrated either in the two murine tumors, or in the three different human neoplastic cell lines studied. If the absence of laminin M is the consequence of neoplastic transformation, then studies of the metabolism of this subunit may provide new information on neoplastic transformation and invasion, and a useful marker in tumor diagnosis. 相似文献
92.
93.
New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. 总被引:13,自引:4,他引:13
下载免费PDF全文
![点击此处可从《Journal of clinical microbiology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
O Ohno M Mizokami R R Wu M G Saleh K Ohba E Orito M Mukaide R Williams J Y Lau 《Journal of clinical microbiology》1997,35(1):201-207
Recent studies have focused on whether different hepatitis C virus (HCV) genotypes are associated with different profiles of pathogenicity, infectivity, and response to antiviral therapy. The establishment of a simple and precise genotyping system for HCV is essential to address these issues. A new genotyping system based on PCR of the core region with genotype-specific PCR primers for the determination of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a was developed. A total of 607 samples (379 from Japan, 63 from the United States, 53 from Korea, 35 from Taiwan, 32 from China, 20 from Hong Kong, 15 from Australia, 6 from Egypt, 3 from Bangladesh, and 1 from South Africa) were tested by both the assay of Okamoto et al. (H. Okamoto, Y. Sugiyama, S. Okada, K. Kurai, Y. Akahane, Y. Sugai, T. Tanaka, K. Sato, F. Tsuda, Y. Miyamura, and M. Mayumi, J. Gen. Virol. 73:673-679, 1992) and this new genotyping system. Comparison of the results showed concordant results for 539 samples (88.8%). Of the 68 samples with discordant results, the nucleotide sequences of the HCV isolates were determined in 23, and their genotypes were determined by molecular evolutionary analysis. In all 23 samples, the assignment of genotype by our new genotyping system was correct. This genotyping system may be useful for large-scale determination of HCV genotypes in clinical studies. 相似文献
94.
95.
Effects of interferon (IFN) on PHA-induced interleukin 2 (IL-2) production by human peripheral mononuclear cells were studied comparatively with natural human IFN-alpha, IFN-beta and IFN-gamma, using an equivalent unit of their antiviral activity ranging from 10 to 1000 IU/ml. IL-2 activity was assessed in cultures with or without IFN by a standard bioassay using murine CTLL-2 cells. PHA-induced production of IL-2 in cultures of peripheral mononuclear cells was unaltered or slightly suppressed by the simultaneous presence of IFN-alpha and IFN-beta. The effect was the same, whether or not indomethacin was present in the cultures. In contrast, the addition of IFN-gamma to the PHA-stimulated cultures markedly enhanced IL-2 production, while IFN-gamma per se had no effect on IL-2 production in the absence of PHA. The enhancement of IL-2 production due to IFN-gamma was more marked in cultures which did not include indomethacin than in cultures which contained indomethacin (1 x 10(-6) M). 相似文献
96.
Kiyoji Kimura Ryuzo Ohno Ichita Amaki Kenichi Hattori Yutaka Hirota Akira Hoshino Michito Ichimaru Munemoto Ito Ikuo Kimura Tadashi Maekawa Toru Masaoka Toru Nakamura Makoto Ogawa Masao Oguro Kazuo Ohta Shigeyuki Osamura Masanori Shimoyama Fumimaro Takaku Yoshiro Uzuka Kazumasa Yamada 《Medical oncology (Northwood, London, England)》1986,3(1):15-24
A phase I study ofN 4-behenoyl-1-β-d-arabinofuranosylcytosine (BHAC) was conducted in 66 patients, 41 with solid tumors and 25 with hematological malignancies. The patients received either a 2-h single intravenous (i.v.) drip infusion (Schedule 1) or consecutive daily 2-h i.v. infusions (Schedule 2). In Schedule 1 the daily dose was initiated with 1.5 mg kg?1 which was escalated up to 7 mg kg?1. Side-effects were mild, and included nausea, vomiting, epilation, and hot flushes. Because of the presence of the solvent vehicle, HCO-60 and in consideration of the mechanism of action of BHAC, the dose escalation was stopped at 7 mg kg?1. In Schedule 2, the daily dose was started with 1.5 mg kg?1 which was escalated up to 8 mg kg?1 and given for 2–16 days. Myelosuppression was found to be dose-limiting toxicity. The maximum tolerated dose (MTD) in patients with non-hematological solid tumors was assumed to be 5 mg kg?1 daily × 5 days. The plasma disappearance curve of BHAC looked biphasic, and when 4 mg kg?1 of BHAC were administered the half-lives of the initial phase (t 1/2α) and the second phase (t 1/2β) were calculated as 0.798 and 5.76 h respectively. In Schedule 2 complete remission was observed in 5 out of 21 patients with acute leukemia, one partial remission in Hodgkin’s disease, and one 1-B response (Karnofsky) in thyroid papillary adenocarcinoma. 相似文献
97.
In order to explore the effects of metals upon the subsequent onset of several clinical events in SMON, a retrospective cohort study was attempted. Study subjects were 216 "exposed" patients and 149 "unexposed" patients. "Exposure" was defined as the simultaneous ingestion of metal-containing drugs with clioquinol before the onset of neurological disorders. These two cohorts were identified from 531 patients among 832 patients, collected by the nationwide survey in 1975 and 1976. Effects provoked by ingestion of five metals (alminum, calcium, magnesium, copper and bismuth) were evaluated by relative risks with and without adjustment of the total amount of clioquinol ingested. Adjusted relative risks were estimated by maximum likelihood method. Significance of relative risk was determined by its 95% confidence interval. Following major findings emerged from the present analysis. (1) Simultaneous ingestion of Al-, Ca-, Mg-, Cu- or Bi-containing drugs with clioquinol significantly reduced the risk of developing motor disturbances. (2) Risk of developing visual disturbances were favorably modified by Al-containing drugs. (3) Clinical severity was significantly reduced by ingestion of Al-, Ca-, Mg- or Bi-containing drugs. (4) About 2-fold increase in risk of unfavorable clinical course was demonstrated by Al-containing drugs. (5) Onset of both green-fur on the tongue and relapse appeared unrelated to the metal-containing drugs ingested. (6) Combined ingestion of two kinds of metal-containing drugs with clioquinol appeared to yield more favorable effects than single ingestion of metal-containing drugs. (7) Al- or Bi-containing drugs demonstrated the strongest association with clinical features of SMON, followed by the drugs containing Mg or Ca. Cu-containing drugs had little association. 相似文献
98.
Fumie Takewaki Hanako Nakajima Daiki Takewaki Yoshitaka Hashimoto Saori Majima Hiroshi Okada Takafumi Senmaru Emi Ushigome Masahide Hamaguchi Masahiro Yamazaki Yoshiki Tanaka Shunji Nakajima Hiroshi Ohno Michiaki Fukui 《Nutrients》2021,13(6)
The aim of this research was to reveal the characteristics of gut microbiome altered by acarbose intervention in Japanese patients with type 2 diabetes (T2D) and its possible association with habitual dietary intake. Eighteen patients with T2D were administered acarbose for four weeks. The abundances of two major phyla, namely Actinobacteria and Bacteroidetes, were reciprocally changed accompanied by the acarbose intervention. There were also significant changes in the abundances of ten genera, including the greater abundance of Bifidobacterium, Eubacterium, and Lactobacillus and the lower abundance of Bacteroides in the group after the intervention than that before the intervention. Hierarchical clustering of habitual dietary intake was performed based on the pattern of changes in the gut microbiota and were classified into distinct three clusters. Cluster I consisted of sucrose, cluster II mainly included fat intake, and cluster III mainly included carbohydrate intake. Moreover, the amount of change in Faecalibacterium was positively correlated with the intake of rice, but negatively correlated with the intake of bread. The intake of potato was negatively correlated with the amount of change in Akkermansia and Subdoligranulum. Acarbose altered the composition of gut microbiome in Japanese patients with T2D, which might be linked to the habitual dietary intake. 相似文献
99.
Yuko Kaneyasu Hisaya Fujiwara Tetsuo Nishimura Hideyuki Sakurai Tomoko Kazumoto Hitoshi Ikushima Takashi Uno Sunao Tokumaru Yoko Harima Hiromichi Gomi Takafumi Toita Midori Kita Shin-ei Noda Takeo Takahashi Shingo Kato Ayako Ohkawa Akiko Tozawa-Ono Hiroki Ushijima Yoko Hasumi Yasuyuki Hirashima Yuzuru Niibe Tomio Nakagawa Tomoyuki Akita Junko Tanaka Tatsuya Ohno the Working Group of the Gynecological Tumor Committee of the Japanese Radiation Oncology Study Group 《Journal of radiation research》2021,62(2):269
This study aimed to research the post-treatment quality of life (QOL) between radiotherapy (RT)- and operation (OP)-treated early cervical cancer survivors, using separate questionnaires for physicians and patients. We administered an observational questionnaire to patients aged 20–70 years old with Stages IB1–IIB cervical cancer who had undergone RT or OP and without recurrence as outpatients for ≥6 months after treatment. We divided 100 registered patients equally into two treatment groups (n = 50 each). The average age was 53 and 44 years in the RT and OP groups, respectively. The RT group included 34 and 66% Stage I and II patients, respectively, whereas the OP group included 66 and 34% Stage I and II patients, respectively. The OP group included 58% of patients with postoperative RT. Combination chemotherapy was performed in 84 and 48% of patients in the RT and OP groups, respectively. On the physicians’ questionnaire, we observed significant differences in bone marrow suppression (RT) and leg edema (OP). On the patients’ questionnaire, significantly more patients had dysuria and leg edema in the OP group than in the RT group, and severe (Score 4–5) leg edema was significantly higher in the post-operative RT group than in the OP only group. The frequency of sexual intercourse decreased after treatment in both groups. On the patients’ questionnaire, there were no significant differences between the two groups regarding sexual activity. These findings are useful to patients and physicians for shared decision-making in treatment choices. The guidance of everyday life and health information including sexual life after treatment is important. 相似文献
100.
Ichihashi T Yamaguchi H Furukawa K Shiku H Naoe T Ohno R 《International journal of oncology》1993,2(4):483-491
We analyzed the genetic origins of anti-GD3 antibodies by comparing nucleotide sequences of the variable regions from the human monoclonal antibody (mAb), 27-26 (mu, k), established from a patient with leukemia, and another human anti-GD3 mAb, HJM-1 (mu, lambda) derived from a patient with melanoma. The variable regions of 27-26 and HJM-1 were remarkably similar to the germ-line genes. The mAb 27-26 was thought to be derived from germ-line repertoire expanded throughout our experiment. HJM-1 was derived from lymphocytes stimulated by GD3 abundantly expressed on melanoma cells. 相似文献